JAK/STAT Pathway Targeting in Primary Sjögren Syndrome

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Primary Sjögren's syndrome (pSS) is a debilitating autoimmune disease impacting exocrine glands, causing dry eyes and mouth.
• pSS pathogenesis involves genetic, epigenetic, and immune system dysregulation, particularly in salivary gland epithelial cells.
• Despite research advances, no specific therapies are currently approved for pSS.

Purpose of the Study:

• To review the current understanding of the Janus kinases (JAK)-signal transducers and activators of transcription (STAT) pathway in pSS.
• To focus on existing research and clinical data concerning JAK inhibitors for pSS treatment.

Main Methods:

• Literature review of basic and translational research on pSS.
• Analysis of studies investigating the JAK-STAT pathway in autoimmune diseases.
• Examination of clinical trial data for JAK inhibitors in pSS.

Main Results:

• The JAK-STAT pathway is crucial in pSS pathogenesis and systemic inflammation.
• JAK inhibitors are emerging as a promising therapeutic strategy for immune-mediated diseases.
• Research indicates potential for JAK inhibitors in managing pSS symptoms.

Conclusions:

• The JAK-STAT pathway represents a significant target for pSS therapy development.
• Further clinical investigation of JAK inhibitors is warranted for pSS treatment.
• Modulating the JAK-STAT pathway offers a novel approach to managing pSS.